Literature DB >> 29720904

Emerging Systemic Therapies for Colorectal Cancer.

Christine M Veenstra1, John C Krauss1.   

Abstract

Despite advances over the past 20 years in colorectal cancer (CRC) screening, diagnosis, and treatment, survival outcomes remain suboptimal. Five-year survival for patients with locally advanced CRC is 69%; 5-year survival drops to 12% for patients with metastatic disease. Novel, effective systemic therapies are needed to improve long-term outcomes. In this review, we describe currently available systemic therapies for the treatment of locally advanced and metastatic CRC and discuss emerging therapies, including encouraging advances in identifying novel targeted agents and exciting responses to immunotherapeutic agents.

Entities:  

Keywords:  clinical trials; colorectal cancer; emerging therapies; immunotherapy; targeted therapy

Year:  2018        PMID： 29720904      PMCID： PMC5929883          DOI： 10.1055/s-0037-1602238

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN： 1530-9681


  87 in total

1.  CTLA-4 regulates induction of anergy in vivo.

Authors:  R J Greenwald; V A Boussiotis; R B Lorsbach; A K Abbas; A H Sharpe
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

4.  Cetuximab for resectable colorectal liver metastasis: new EPOC trial.

Authors:  Kiyoshi Hasegawa; Masaru Oba; Norihiro Kokudo
Journal:  Lancet Oncol       Date:  2014-07       Impact factor: 41.316

5.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 6.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

7.  Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Authors:  Rodrigo Dienstmann; Amita Patnaik; Rocio Garcia-Carbonero; Andrés Cervantes; Marta Benavent; Susana Roselló; Bastiaan B J Tops; Rachel S van der Post; Guillem Argilés; Niels J Ø Skartved; Ulla H Hansen; Rikke Hald; Mikkel W Pedersen; Michael Kragh; Ivan D Horak; Stephan Braun; Eric Van Cutsem; Anthony W Tolcher; Josep Tabernero
Journal:  Cancer Discov       Date:  2015-05-11       Impact factor: 39.397

8.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

Review 9.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

10.  HER2/neu testing in primary colorectal carcinoma.

Authors:  B Ingold Heppner; H-M Behrens; K Balschun; J Haag; S Krüger; T Becker; C Röcken
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640
View more
  10 in total

1.  Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells.

Authors:  JaeJin An; Eun-Mi Ha
Journal:  J Microbiol       Date:  2022-07-04       Impact factor: 3.422

2.  Glutathione Peroxidase 4 as a Therapeutic Target for Anti-Colorectal Cancer Drug-Tolerant Persister Cells.

Authors:  Xiaoli Zhang; Yiming Ma; Jianhui Ma; Lan Yang; Qingzhi Song; Hongying Wang; Guoqing Lv
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

3.  Thymidylate Synthase Overexpression Drives the Invasive Phenotype in Colon Cancer Cells.

Authors:  Wojciech M Ciszewski; Małgorzata Chmielewska-Kassassir; Lucyna A Wozniak; Katarzyna Sobierajska
Journal:  Biomedicines       Date:  2022-05-29

Review 4.  MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Authors:  Fahima Danesh Pouya; Maria Gazouli; Yousef Rasmi; Dimitra Ioanna Lampropoulou; Mohadeseh Nemati
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

5.  Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells.

Authors:  Chiara Zichittella; Maria Magdalena Barreca; Aurora Cordaro; Chiara Corrado; Riccardo Alessandro; Alice Conigliaro
Journal:  BMC Cancer       Date:  2022-05-20       Impact factor: 4.638

6.  Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?

Authors:  Ruth Vera; Elena Mata; Encarna González; Ignacio Juez; Vicente Alonso; Patricia Iranzo; Nieves P Martínez; Carlos López; José M Cabrera; María J Safont; Ana Ruiz-Casado; Mercedes Salgado; Beatriz González; Pilar Escudero; Fernando Rivera; Carles Pericay
Journal:  Int J Colorectal Dis       Date:  2020-02-15       Impact factor: 2.571

Review 7.  DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Authors:  Julian Maier; Felix P Mayer; Simon D Brandt; Harald H Sitte
Journal:  ACS Chem Neurosci       Date:  2018-10-05       Impact factor: 5.780

8.  Effects of wogonin on the growth and metastasis of colon cancer through the Hippo signaling pathway.

Authors:  Wenli You; Aiting Di; Lize Zhang; Gang Zhao
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

9.  Identification of key genes involved in the development and progression of early-onset colorectal cancer by co-expression network analysis.

Authors:  Xiaoqiong Mo; Zexin Su; Bingsheng Yang; Zhirui Zeng; Shan Lei; Hui Qiao
Journal:  Oncol Lett       Date:  2019-11-08       Impact factor: 2.967

Review 10.  5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes.

Authors:  Sabrina Blondy; Valentin David; Mireille Verdier; Muriel Mathonnet; Aurélie Perraud; Niki Christou
Journal:  Cancer Sci       Date:  2020-08-13       Impact factor: 6.716
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.